Kate A Boonen

Learn More
BACKGROUND Three novel direct oral anticoagulants (DOACs) have recently been registered by the Food and Drug Administration and European Medicines Agency Commission: dabigatran, rivaroxaban, and apixaban. To quantify DOACs in plasma, various dedicated coagulation assays have been developed. OBJECTIVE To develop and validate a reference ultra-performance(More)
Major orthopaedic surgery is associated with an increased risk of venous thromboembolism. Direct oral anticoagulants (DOACs) are recommended as thromboprophylactic agents after orthopaedic surgery. Although routine monitoring of DOACs in general is not required, measuring DOAC concentration may be necessary in clinical settings. The effects of DOACs on(More)
Ohlsson, Claes; Nilsson, Maria E; Tivesten, Asa; Ryberg, Henrik; Mellström, Dan; Karlsson, Magnus; Ljunggren, Osten; Labrie, Fernand; Orwoll, Eric S; Lee, David M; Pye, Stephen R; O'Neill, Terence W; Finn, Joseph D; Adams, Judith E; Ward, Kate A; Boonen, Steven; Bartfai, Gyorgy; Casanueva, Felipe F; Forti, Gianni; Giwercman, Aleksander; Han, Thang S;(More)
  • 1